Get the Stockscreener App
225.18
0.98%
2.19
Pre-market:
225.78
0.60
+0.27%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $225.18, with a volume of 8.52M.
It is up +0.98% in the last 24 hours and up +2.96% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$222.99
Open:
$225
24h Volume:
8.52M
Relative Volume:
1.44
Market Cap:
$397.98B
Revenue:
$59.64B
Net Income/Loss:
$2.36B
P/E Ratio:
169.91
EPS:
1.3253
Net Cash Flow:
$19.68B
1W Performance:
-2.20%
1M Performance:
+2.96%
6M Performance:
+18.83%
1Y Performance:
+28.18%
1-Day Range:
$221.00
$225.98
1-Week Range:
$220.23
$230.94
52-Week Range:
$164.39
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
225.18 | 394.11B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
LLY
Lilly Eli Co
|
993.64 | 879.11B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
206.54 | 481.76B | 92.15B | 25.12B | 20.46B | 10.36 |
|
NVS
Novartis Ag Adr
|
131.19 | 251.38B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
97.62 | 240.48B | 63.90B | 19.05B | 13.05B | 7.5596 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
DISCO Pharmaceuticals Appoints Mark Manfredi as CEO and Announces Final Close of €36 Million Seed Financing - GlobeNewswire Inc.
HSBC Upgrades AbbVie (ABBV) to Buy, Raises Price Target to $265 - Finviz
AbbVie: Unique Mix Of Growth And Value (NYSE:ABBV) - Seeking Alpha
ASH 2025: AbbVie and Genmab’s Epkinly sets new standard in second-line FL - Yahoo Finance
AbbVie upgraded, Biogen downgraded as HSBC reflects on 2026 in pharma - MSN
AbbVie upgraded, Biogen downgraded at HSBC (BIIB:NASDAQ) - Seeking Alpha
Crohn’s Disease Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | AbbVie, Merck, Eli Lilly and Company, RedHill Biopharma, Bristol Myers Squibb, Dr. Falk Pharma GmbH - Barchart.com
Here Are Wednesday’s Top Wall Street Analyst Research Calls: AbbVie, Amazon.com, Biogen, EchoStar, Ferrari, GE Vernova, PepsiCo, Take-Two Interactive, and More - Yahoo Finance
AbbVie Stock (ABBV) Opinions on Analyst Upgrade and Pipeline Developments - Quiver Quantitative
Here Are Wednesday's Top Wall Street Analyst Research Calls: AbbVie, Amazon.com, Biogen, EchoStar, Ferrari, GE Vernova, PepsiCo, Take-Two Interactive, and More - 24/7 Wall St.
This AbbVie Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
Analyst recommendations: Abbvie, Biogen, PepsiCo, Eli Lilly, Netflix… - marketscreener.com
HSBC Upgrades AbbVie to Buy From Hold, Adjusts Price Target to $265 From $225 - marketscreener.com
Investment Management Corp of Ontario Has $19.88 Million Position in AbbVie Inc. $ABBV - MarketBeat
iSAM Funds UK Ltd Takes $3.39 Million Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Bought by State Street Corp - MarketBeat
Daiwa Securities Group Inc. Buys 38,862 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie (ABBV) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
AbbVie (NYSE:ABBV) Shares Down 1.4%Here's Why - MarketBeat
How Investors May Respond To AbbVie (ABBV) Expanding Its Pipeline With New Migraine And Oncology Data - Yahoo Finance
Why Investors Shouldn't Be Surprised By AbbVie Inc.'s (NYSE:ABBV) Low P/S - 富途牛牛
Ose Immunotherapeutics stock falls after AbbVie deal amendment By Investing.com - Investing.com UK
SVB Wealth LLC Sells 113,330 Shares of AbbVie Inc. $ABBV - MarketBeat
Ossiam Has $51.75 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
Gabelli Funds LLC Cuts Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Jump Financial LLC Buys New Shares in AbbVie Inc. $ABBV - MarketBeat
OSE Immunotherapeutics Amends Partnership With AbbVie for Inflammation Drug Development - marketscreener.com
OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development - Yahoo Finance
Ophthalmic Drugs Market Size to Cross USD 62.74 Billion by 2032, Driven by Advances in Eye Care Treatments and Rising Global Vision Disorders - GlobeNewswire Inc.
Federated Hermes Inc. Acquires 134,942 Shares of AbbVie Inc. $ABBV - MarketBeat
California Public Employees Retirement System Sells 778,732 Shares of AbbVie Inc. $ABBV - MarketBeat
Cerity Partners LLC Has $210.15 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
Stenger Family Office LLC Takes Position in AbbVie Inc. $ABBV - MarketBeat
SCS Capital Management LLC Increases Stock Position in AbbVie Inc. $ABBV - MarketBeat
1832 Asset Management L.P. Increases Stock Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie (NYSE:ABBV) Shares Down 1.1%What's Next? - MarketBeat
Mirabella Financial Services LLP Has $2.41 Million Position in AbbVie Inc. $ABBV - MarketBeat
Marshall Wace LLP Grows Stake in AbbVie Inc. $ABBV - MarketBeat
M Holdings Securities Inc. Increases Holdings in AbbVie Inc. $ABBV - MarketBeat
Quantbot Technologies LP Takes Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Bought by Brown Advisory Inc. - MarketBeat
Amundi Purchases 2,435,372 Shares of AbbVie Inc. $ABBV - MarketBeat
Arrowstreet Capital Limited Partnership Has $58.79 Million Stake in AbbVie Inc. $ABBV - MarketBeat
AbbVie-Sponsored Symposium at ESMO Asia 2025 Highlights Urgent Medical Need in Platinum-Resistant Advanced Ovarian Cancer - PR Newswire
Is AbbVie Inc. (4AB) stock undervalued after correctionWeekly Trade Summary & Community Consensus Picks - Newser
How Strong Is AbbVie's Immunology Franchise After Humira's LOE? - The Globe and Mail
Could buying AbbVie today set you up for life? - MSN
Could Buying AbbVie Today Set You Up for Life? - Nasdaq
Dry Eye Disease Treatment Market Outlook Report 2032 | Alcon - openPR.com
Kennedy Capital Management LLC Reduces Holdings in AbbVie Inc. $ABBV - MarketBeat
Why AbbVie Inc. stock attracts global investorsMarket Performance Summary & Fast Exit and Entry Strategy Plans - Newser
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):